vTv Therapeutics Inc. VTVT
23.55 USD -0.60 (-2.48%)
At closeNov 3, 2026, 4:01 PM EST
23.55 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
22.85 Day range 25.26
22.45 52-week range 44.00
- YTD
- -41.11%
- 1 year
- +0.64%
News
benzinga.com vTv Therapeutics Announces First Patient Randomized In Phase 2a Hybrid CATT1 Study Of Cadisegliatin In Type 1 Diabetes Phase 2a pilot study aims to inform the design and conduct of future Phase 3 research in this populationCadisegliatin is a potential first-in-class oral therapy being evaluated as an adjunct to…
globenewswire.com vTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery Systems Phase 2a pilot study aims to inform the design and conduct of future Phase 3 research in this population Cadisegliatin is a potential first-in-class oral therapy being evaluated as an adjunct to…
seekingalpha.com vTv Therapeutics Inc. (VTVT) Discusses Hypoglycemia Burden in Type 1 Diabetes and Cadisegliatin Phase 3 Program Transcript vTv Therapeutics Inc. (VTVT) Discusses Hypoglycemia Burden in Type 1 Diabetes and Cadisegliatin Phase 3 Program Transcript
marketbeat.com vTv Therapeutics Highlights Cadisegliatin's Phase III Push to Tackle Type 1 Hypoglycemia vTv Therapeutics NASDAQ: VTVT used a virtual key opinion leader event to outline the continuing burden of hypoglycemia in type 1 diabetes, present patient and physician market-research findings, and…
benzinga.com vTv Therapeutics Receives FDA's Orphan Drug Designation For HPPD To Treat Sickle Cell Disease vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that the U.S. Food…
globenewswire.com vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease Milestone supports partnering discussions for HPPD as the Company continues to prioritize its lead late-stage type 1 diabetes (T1D) program, cadisegliatin Milestone supports partnering discussions…
globenewswire.com vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026 HIGH POINT, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type…
defenseworld.net Financial Comparison: Jazz Pharmaceuticals (NASDAQ:JAZZ) vs. vTv Therapeutics (NASDAQ:VTVT) Jazz Pharmaceuticals (NASDAQ: JAZZ - Get Free Report) and vTv Therapeutics (NASDAQ: VTVT - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two…- benzinga.com vTv Therapeutics Completes Enrollment In Its Phase 3 Cadisegliatin As Adjunctive Therapy In Type 1 Diabetes Trial vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that the Company…
globenewswire.com vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D) Milestone advances Phase 3 program toward topline results expected in mid 2027 Milestone advances Phase 3 program toward topline results expected in mid 2027
defenseworld.net Theravance Biopharma (NASDAQ:TBPH) versus vTv Therapeutics (NASDAQ:VTVT) Head-To-Head Contrast vTv Therapeutics (NASDAQ: VTVT - Get Free Report) and Theravance Biopharma (NASDAQ: TBPH - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare…
globenewswire.com vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) HIGH POINT, N.C., Sept. 15, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential…
globenewswire.com vTv Therapeutics to Participate in September Investor Conferences HIGH POINT, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for…
globenewswire.com vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) HIGH POINT, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential…
benzinga.com HC Wainwright & Co. Maintains Buy on vTv Therapeutics, Lowers Price Target to $42 HC Wainwright & Co. analyst Emily Bodnar maintains vTv Therapeutics (NASDAQ:VTVT) with a Buy and lowers the price target from $45 to $42.
benzinga.com vTv Therapeutics Q2 EPS $(1.05) Misses $(0.99) Estimate vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(0.99) by 6.06 percent. This is a 14.13 percent decrease over losses of…
globenewswire.com vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026 Cadisegliatin Phase 2a hybrid closed-loop trial…
globenewswire.com vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) HIGH POINT, N.C., July 28, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential…
benzinga.com Abbott To Rally More Than 35%? Here Are 10 Top Analyst Forecasts For Friday Recent analyst rating changes, top names such as PPG, SAH, ISRG, MMM, OKE, GLDG, ABT, NFLX, TSCO, and SBAC were upgraded or downgraded.
benzinga.com BlackRock To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Thursday Top Wall Street analysts changed their outlook on top names. See all changes, including upgrades and downgrades, on our analyst ratings page.
benzinga.com BTIG Maintains Buy on vTv Therapeutics, Raises Price Target to $57 BTIG analyst Kambiz Yazdi maintains vTv Therapeutics (NASDAQ:VTVT) with a Buy and raises the price target from $49 to $57.
globenewswire.com vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) HIGH POINT, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential…
globenewswire.com vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) HIGH POINT, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential…
zacks.com vTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be Sustainable If you are looking for stocks that are well positioned to maintain their recent uptrend, vTv Therapeutics (VTVT) could be a great choice. It is one of the several stocks that passed through our…
benzinga.com vTv Therapeutics Q1 EPS $1.65 Beats $(0.10) Estimate, Sales $36.839M Beat $20.000M Estimate vTv Therapeutics (NASDAQ:VTVT) reported quarterly earnings of $1.65 per share which beat the analyst consensus estimate of $(0.10) by 1933.33 percent. This is a 314.29 percent increase over losses of…
globenewswire.com vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Phase 3 CATT1 completion of enrollment on track for the third quarter of 2026 Strong balance sheet expected to fund operations through anticipated CATT1 topline data readout HIGH POINT, N.C., May 13,…
globenewswire.com vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) HIGH POINT, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential…
globenewswire.com vTv Therapeutics to Participate in Upcoming May Investor Conferences HIGH POINT, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential…
zacks.com Wall Street Analysts See a 39.9% Upside in vTv Therapeutics (VTVT): Can the Stock Really Move This High? The mean of analysts' price targets for vTv Therapeutics (VTVT) points to a 39.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement…
benzinga.com This Karman Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Wall Street analysts changed outlook on top names. See ratings page for upgrades, downgrades, and initiations. Analysts recommend H2O, KRMN, GNSS, WCN, and WM stocks.
benzinga.com This Nio Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday 
benzinga.com This EverCommerce Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday Wall Street analysts change outlook on top companies. See analyst rating changes and their thoughts on EVCM stock before buying.
benzinga.com This General Mills Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday Top Wall Street analysts changed their outlook on top names, including WLTH, FPI, CAG, VIV, and GIS. See what other analysts think of FPI stock.
benzinga.com This Jabil Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Top Wall Street analysts changed outlook on certain stocks. See analyst ratings and advice on Rush Street, Jabil, Enovix, Planet Fitness, and vTv Therapeutics.- benzinga.com Evercore ISI Group Initiates Coverage On vTv Therapeutics with Outperform Rating, Announces Price Target of $44 Evercore ISI Group analyst Michael DiFiore initiates coverage on vTv Therapeutics (NASDAQ:VTVT) with a Outperform rating and announces Price Target of $44.
- benzinga.com vTv Therapeutics Q4 EPS $(0.58) Beats $(1.17) Estimate vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(1.17) by 50.21 percent. This is a 5.45 percent decrease over losses of…
benzinga.com vTv Therapeutics Expands License Deal With Newsoara Biopharma To Offer Global Rights To PDE4 Inhibitor vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being…- benzinga.com BTIG Maintains Buy on vTv Therapeutics, Raises Price Target to $49 BTIG analyst Kambiz Yazdi maintains vTv Therapeutics (NASDAQ:VTVT) with a Buy and raises the price target from $40 to $49.
benzinga.com This MasTec Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday 
benzinga.com Roth Capital Initiates Coverage On vTv Therapeutics with Buy Rating, Announces Price Target of $58 Roth Capital analyst Adam Walsh initiates coverage on vTv Therapeutics (NASDAQ:VTVT) with a Buy rating and announces Price Target of $58.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
benzinga.com This vTv Therapeutics Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday 
benzinga.com TD Cowen Initiates Coverage On vTv Therapeutics with Buy Rating, Announces Price Target of $67 TD Cowen analyst Ritu Baral initiates coverage on vTv Therapeutics (NASDAQ:VTVT) with a Buy rating and announces Price Target of $67.
benzinga.com HC Wainwright & Co. Maintains Buy on vTv Therapeutics, Raises Price Target to $47 HC Wainwright & Co. analyst Emily Bodnar maintains vTv Therapeutics (NASDAQ:VTVT) with a Buy and raises the price target from $36 to $47.- benzinga.com vTv Therapeutics And M42's IROS Submits Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health; This Study Constitutes The Longest Trial Investigating Cadisegliatin To Date vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company, today announced a Phase 2 clinical study protocol developed in collaboration with M42's Insights Research Organization &…
- benzinga.com BTIG Initiates Coverage On vTv Therapeutics with Buy Rating, Announces Price Target of $40 BTIG analyst Kambiz Yazdi initiates coverage on vTv Therapeutics (NASDAQ:VTVT) with a Buy rating and announces Price Target of $40.
- benzinga.com vTv Therapeutics Q3 EPS $(1.08) Misses $(0.98) Estimate vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.98) by 10.2 percent. This is a 22.73 percent decrease over losses of…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Why AMD Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session